Zum Hauptinhalt springen
xMedica

NCT06033274ClinicalTrials.gov

Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment

Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment: the TRIPLACE Registry

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

The field of transcatheter tricuspid valve replacement (TTVR) is rapidly emerging and data on this topic are scarce. Particularly, little is known about which patients are at greatest risk of procedural complications, such as the timing and onset of conduction…

Beobachtend800 Teilnehmende gesucht31 Studienzentren8 Länder

Kategorien

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2023-09-13; recorded start 2023-10-05
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 112 other studies in this databaseCounted from the lead sponsor named in the record (Montefiore Medical Center)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: other.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 21 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 800 participants (target), run at 31 sites, across 8 countries.

How this score is built
  • Enrolment29/40

    800 participants (target)

  • Site count16/25

    21 sites

  • Country count12/15

    7 countries

  • Planned duration8/10

    Planned over about 34 months

  • Sponsor scale8/10

    Montefiore Medical Center has led 112 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

The field of transcatheter tricuspid valve replacement (TTVR) is rapidly emerging and data on this topic are scarce. Particularly, little is known about which patients are at greatest risk of procedural complications, such as the timing and onset of conduction disturbances necessitating permanent pacemaker implantation, and how such patients are managed. On this background, the TRIPLACE Registry - an investigator-initiated global multicenter registry - is aimed at better understanding the safety and efficacy of orthotopic TTVR.

The primary aims of the registry will be: * To examine the safety, efficacy, and long-term outcomes of TTVR * To assess the incidence of procedural complications and their correlations with adverse clinical outcomes * To investigate the impact of different pre/post-procedural factors on peri-procedural complications and long-term outcomes after TTVR * To explore the characteristics of patients deemed eligible for TTVR.

Erkrankungen

  • Tricuspid Regurgitation

Eignung

Eignung
GeschlechtAlle
Alter18 YearsKein Höchstalter
Gesunde FreiwilligeNein
StichprobenverfahrenNON_PROBABILITY_SAMPLE

Studienpopulation

Patients undergoing orthotopic Transcatheter Tricuspid Valve Replacement for clinically significant tricuspid valve disease.

Eignung im Wortlaut des Registers

Inclusion Criteria: * Patients undergoing Transcatheter Tricuspid Valve Replacement * Native Tricuspid Valve disease * Orthotopic Tricuspid Valve Implantation Exclusion Criteria: * Age under 18 years

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
StudientypBeobachtend
PhaseIm Registereintrag nicht angegeben
ZuteilungIm Registereintrag nicht angegeben
InterventionsmodellIm Registereintrag nicht angegeben
Primäres ZielIm Registereintrag nicht angegeben
VerblindungIm Registereintrag nicht angegeben
Teilnahme800 Teilnehmende gesucht

Sponsor und Mitwirkende

  • Montefiore Medical Center Sponsor
  • The Cleveland Clinic Mitwirkende
  • University of Toronto Mitwirkende
  • University Hospital, Bordeaux Mitwirkende

Studienarme und Interventionen

  • Patients with Tricuspid Regurgitation undergoing Transcatheter Tricuspid Valve Replacement

    Patients having clinically significant tricuspid regurgitation, defined according to current guidelines (ESC/EACTS and ACC/AHA) for valvular heart disease, requiring transcatheter tricuspid valve replacement

Interventionen

  • Medizinprodukt Transcatheter Tricuspid Valve Replacement

    All patients undergoing Transcatheter Tricuspid Valve Replacement for native tricuspid valve disease

Endpunkte

  1. Primärer Endpunkt

    Freedom from device-related complications

    Freedom from device-related complications will be determined by assessing the number of participants with procedural, peri-procedural and device-related complications

    Zeitrahmen 30 days after the index procedure

  2. Primärer Endpunkt

    Reduction in Tricuspid Regurgitation Severity

    Tricuspid Regurgitation measured by transthoracic echocardiography. Assessment of MI severity according to current guidelines (ESC/EACTS and ACC/AHA) for valvular heart disease. Tricuspid Regurgitation is measured by transthoracic echocardiography in accordance with current guidelines (ESC/EACTS and ACC/AHA) for valvular heart disease. Mean tricuspid regurgitation severity will be determined using the following scale: 0=none/trace; 1=mild; 2=moderate; 3=severe; 4=massive; 5=torrential. Change from baseline tricuspid regurgitation severity score 30 days after baseline will be assessed

    Zeitrahmen 30 days after the index procedure

  3. Sekundärer Endpunkt

    Tricuspid Valve Reintervention

    The number of participants who undergo tricuspid valve surgical and/or transcatheter reintervention will be summed and recorded

    Zeitrahmen 12 months after the index procedure

  4. Sekundärer Endpunkt

    Permanent Pacemaker Implantation

    The number of participants who have received a permanent pacemaker implantation will be recorded

    Zeitrahmen 30 days after the index procedure

  5. Sekundärer Endpunkt

    Combined all-cause mortality or rehospitalization for congestive heart failure

    The composite of mortality from any cause and participants re-hospitalized for acute decompensated congestive heart failure will be recorded

    Zeitrahmen 12 months after the index procedure

  6. Sekundärer Endpunkt

    All-cause mortality

    The number of deaths due to any cause will be recorded

    Zeitrahmen 12 months after the index procedure

  7. Sekundärer Endpunkt

    Hospitalization for congestive heart failure

    The number of participants who have been hospitalized with acute decompensated congestive heart failure will be recorded

    Zeitrahmen 12 months after the index procedure

  8. Sekundärer Endpunkt

    The number of participants with New York Heart Association (NYHA) Stage III or IV heart failure

    The number of participants who meet either NYHA III or NYHA IV classifications for heart failure will be recorded. NYHA Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m).Comfortable only at rest NYHA Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients

    Zeitrahmen 12 months after the index procedure

  9. Sekundärer Endpunkt

    Device Thrombosis

    The number of participants who have been identified with device thrombosis will be recorded

    Zeitrahmen 12 months after the index procedure

  10. Sekundärer Endpunkt

    Tricuspid Regurgitation Severity

    Tricuspid Regurgitation is measured by transthoracic echocardiography. Assessment of MI severity will be conducted in accordance with current guidelines (ESC/EACTS and ACC/AHA) for valvular heart disease. Mean tricuspid regurgitation severity will be determined using the following scale: 0=none/trace; 1=mild; 2=moderate; 3=severe; 4=massive; 5=torrential. Higher mean scores are indicative of greater TR severity

    Zeitrahmen 12 months after the index procedure

  11. Sekundärer Endpunkt

    Quality of Life - Kansas City Cardiomyopathy Questionnaire

    Quality of Life is evaluated using the Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ has a 2-week recall period and includes 23 items that map to 7 domains: symptom frequency; symptom burden; symptom stability; physical limitations; social limitations; quality of life; and self-efficacy (the patient's understanding of how to manage their heart failure). The symptom frequency and symptom burden domains are merged into a total symptom score, which can be combined with the physical limitation domain to create a clinical summary score that mirrors the key concepts of the NYHA functional class. The symptom, physical limitations, social limitations, and quality of life domains are combined to create an overall summary score, which is the primary health status outcome All scores are represented on a 0-to-100-point scale, where lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life

    Zeitrahmen 12 months after the index procedure

Daten

Daten
Startdatum5. Oktober 2023 (tatsächlich)
Primärer Abschluss1. Dezember 2028 (geschätzt)
Abschluss1. Dezember 2028 (geschätzt)
Erstveröffentlichung13. September 2023 (tatsächlich)
Zuletzt aktualisiert15. September 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtSeptember 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

30 Studienzentren rekrutieren

Canada

Canada
EinrichtungStadtBundesland oder RegionStatus
Montréal Heart Institute (MHI)MontrealQuebecRekrutiert
Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, CanadaQuébecQuebecRekrutiert
St Michael's Hospital, University of TorontoTorontoOntarioRekrutiert
St. Paul's HospitalVancouverBritish ColumbiaRekrutiert

Denmark

Denmark
EinrichtungStadtBundesland oder RegionStatus
Rigshospitalet, Copenhagen University HospitalCopenhagenCapital RegionRekrutiert

France

France
EinrichtungStadtBundesland oder RegionStatus
Chu De Bordeaux - Haut-Lévêque HospitalBordeauxPessacRekrutiert
Centre Hospitalier Universitaire de LilleLilleHauts-de-FranceRekrutiert
Hospital Center University De Lille (CHU Lille)LilleHauts-de-FranceRekrutiert
Clinique Pasteur ToulouseToulouseHaute-GaronneRekrutiert

Germany

Germany
EinrichtungStadtBundesland oder RegionStatus
Heart and Diabetes Centre, North Rhine-Westphalia (NRW), Ruhr-UniversityBad OeynhausenRekrutiert
Heart Center Cologne, University of CologneCologneRekrutiert
University of Duisberg-Essen, West German Heart and Vascular CentreEssenNorth Rhine-WestphaliaRekrutiert
Cardiovascular Center (CVC) Frankfurt, Division of CardiologyFrankfurt am MainHesseRekrutiert
University Heart and Vascular Center, Department of CardiologyHamburgRekrutiert
University Heart Center, Schleswig-Holstein UniversityLübeckSchleswig-HolsteinRekrutiert
Medical Clinic and Polyclinic, University Hospital of Munich (LMU Klinikum)MunichBavariaRekrutiert

Italy

Italy
EinrichtungStadtBundesland oder RegionStatus
Centro Cardiologico Monzino IRCCSMilanLombardyRekrutiert
San Raffaele University HospitalMilanLombardyRekrutiert

Spain

Spain
EinrichtungStadtBundesland oder RegionStatus
Hospital Clínico Universitario de ValladolidValladolidRekrutiert
University Hospital Alvaro Cunqueiro (CHUVI)VigoPontevedraRekrutiert

Switzerland

Switzerland
EinrichtungStadtBundesland oder RegionStatus
University Hospital BaselBaselCanton of Basel-CityRekrutiert
HerzZentrum Hirslanden ZürichZurichRekrutiert

United States

United States
EinrichtungStadtBundesland oder RegionStatus
The Christ HospitalCincinnatiOhioRekrutiert
Cleveland ClinicClevelandOhioRekrutiert
Hackensack University Medical CenterHackensackNew JerseyRekrutiert
Columbia University Irving Medical CenterNew YorkNew YorkRekrutiert
Arizona Heart Hospital (Biltmore Cardiology)PhoenixArizonaRekrutiert
Oregon Health & Science UniversityPortlandOregonNicht angegeben
Providence St. Vincent Medical CenterPortlandOregonRekrutiert
Montefiore Medical CenterThe BronxNew YorkRekrutiert
Ascension Via ChristiWichitaKansasRekrutiert

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

  1. 15. September 2026

    Abschlussdatum nach hinten verschoben

    Primary completion delayed 853 days

    2026-08-012028-12-01

  2. 15. September 2026

    Studienzentrum hinzugefügt

    10 sites added (31 total)

    2131